Surrozen, Inc/de 10-Q quarterly reports

Surrozen, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing progress in its Wnt pathway modulation platform for ophthalmology and reporting a net loss.

Surrozen, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $127.5 million and continued investment in its Wnt pathway-modulating therapeutics for ophthalmic diseases.

Surrozen, Inc. reported a significant net loss of $71.6 million for Q3 2025, driven by non-cash charges and increased R&D for its ophthalmology pipeline, while discontinuing its SZN-043 program and facing termination of a key research collaboration.

Surrozen, Inc. reported a net income of $39.7 million for Q2 2025, driven by non-cash gains from warrant and tranche liability fair value adjustments, and secured significant funding for its ophthalmology pipeline.

Surrozen Inc. announces its financial results for the first quarter of 2025, focusing on the progress of its ophthalmology programs and recent financing activities.

Surrozen Inc. announced its Q3 2024 financial results, including a $10 million milestone payment from Boehringer Ingelheim and a net loss of $1.4 million.

Surrozen, Inc. released its second quarter 2024 results, detailing financial performance and progress in clinical development, including the initiation of a Phase 1b trial for SZN-043.

Surrozen, Inc. announced its first quarter 2024 financial results, highlighting ongoing clinical trial progress and a recent private placement for additional funding.